which is important-whether or not it can be measured accurately.

DIANA BRINKLEY

Consultant Radiotherapist, South East London Radiotherapy Centre, King's College Hospital, London SE5 9RS

1 Karnofsky D, Burchenal IH. Clinical evaluation of chemotherapeutic agents in cancer. In: Macleod CM, ed. Evaluation of chemotherapeutic agents. New York: Columbia University Press, 1949.
 Hunt SM, McEwen J, McKenna SP. Measuring health status: a new tool for clinicians and epidemiologists. J R Coll Gen Pract 1985;35:185-8.

- 3 Grogono AW, Woodgate DJ. Index for measuring health. Lancet 1971;ii:1024-6
- 4 Fayers PM, Jones DR. Measuring and analysing quality of life in cancer clinical trials: a review. Statistics in medicine. Vol 2. Bristol: John Wiley and Sons Ltd, 1983:429-46.
- 5 Steinburg MD, Juliano MA, Wise L. Psychological outcome of lumpectomy versus mastectomy in the treatment of breast cancer. Am 7 Psychiatry 1985;142:34-9.
- 6 Priestman TJ, Baum M. Evaluation of quality of life in patients receiving treatment for advanced breast cancer. Lancet 1976;j:899-901.
- 7 Spitzer WO, Dobson AJ, Hall J, et al. Measuring the quality of life of cancer patients. J Chronic Dis 1981;34:585-97.

Cranial irradiation in childhood lymphoblastic leukaemia: time for reappraisal?

Fifteen years ago the first Medical Research Council United Kingdom acute lymphoblastic leukaemia trial introduced Britain to the concept of treatment to prevent overt leukaemic infiltration of the central nervous system, so called "central nervous system prophylaxis."1 Without such prophylaxis most children who survive lymphoblastic leukaemia go on to develop this complication. Established leukaemia in the central nervous system is difficult to eradicate, causes considerable discomfort, and is associated with a risk of further neurological complications.² Thus central nervous system prophylaxis proved a welcome advance and one which, coupled with intensified combination therapy, has led to growing numbers of cures in children with acute lymphoblastic leukaemia.

The method of prophylaxis introduced in the Medical Research Council United Kingdom acute lymphoblastic leukaemia I and II trials-and which had been pioneered in St Jude Children's Research Hospital in Memphiscomprised a course of cranial irradiation in a dose of 2400 rads (cGy), usually given in 15 fractions over three weeks with concomitant intrathecal methotrexate or spinal irradiation or both.³⁴ The combination of cranial irradiation, 2400 rads, and intrathecal methotrexate was widely adopted as standard prophylaxis in Britain and many centres abroad, although some centres have never used cranial irradiation or abandoned it in favour of alternative methods, such as moderate dose intravenous methotrexate with intrathecal methotrexate,⁵ or triple intrathecal chemotherapy.⁶

The possibility that cranial irradiation might impair cerebral function has long been considered⁷ but has been difficult to prove because of the problems of prospective studies in a disease with a high attrition rate, the need for long term follow up, the young age of the most vulnerable patients, and the compounding social and emotional problems that are encountered in children with acute lymphoblastic leukaemia and their families.8 Not surprisingly, therefore, many reported studies of intellectual function have been retrospective or based on relatively small numbers of patients, or both.⁹⁻¹¹ Nevertheless, these reports show that children who have received "standard" central nervous system prophylaxis usually function intellectually within the normal range but tend to perform less well than their siblings or social peers. Differences are most appreciable in young children, particularly those under 3 at the time of diagnosis, whose schooling is least likely to have been interrupted by treatment.12 More extensive assessment of cognitive function shows a wide range of functional defects in areas such as memory and attention, speed of processing information, and auditory learning¹³ (L Jannoun, J M Chessells, paper submitted for publication). These deficits are not usually apparent on routine screening or intelligence testing alone. A recent retrospective survey has shown that children whose prophylaxis included cranial irradiation performed significantly less well than those receiving intrathecal methotrexate alone, or intrathecal and intravenous methotrexate.¹⁴ These observations-which obviously implicate cranial irradiation -require confirmation in view of reports where abnormalities in computed tomograms occurred irrespective of whether the child had received cranial irradiation.^{15 16} Regrettably, in view of the increasing use of bone marrow transplantation there are no reports of neuropsychological function after total body irradiation.

Cranial irradiation causes abnormalities of hypothalamic pituitary function, especially production of growth hormone. Shalet and his colleagues have systematically evaluated endocrine function in children treated for acute lymphoblastic leukaemia and children with brain tumours.¹⁷⁻²⁰ They estimate that a minimum dose of 2500-2900 rads given over three weeks, or an equivalent radiobiological dose, is needed to produce clinically overt deficiency of growth hormone,¹⁷ and in a recent paper have shown that in some patients at least the abnormality is due to deficiency of hypothalamic growth hormone releasing factor.¹⁸ Although provocation tests in children receiving standard treatment for acute lymphoblastic leukaemia may disclose abnormalities of growth hormone secretion,¹⁹ any substantial impairment of growth is exceptional.²⁰ Patients receiving a second course of cranial irradiation, however, are clearly at risk of hypothalamicpituitary failure and require careful follow up. The main cause of impairment of growth after total body irradiation is gonadal failure, but here again hypothalamic pituitary failure may be a contributory factor.²¹

So what is the place of cranial irradiation in childhood acute lymphoblastic leukaemia? The American Children's Cancer Study Group showed that 1800 rads is as effective as 2400 rads, although not perhaps for children with a high initial leucocyte count,²² and the Medical Research Council has adopted this lower dose regimen together with a policy of deferred irradiation in children aged under 2 years. Neither group, however, has appreciably decreased the size of individual treatment fractions and it remains to be seen whether this lower total dose of radiation is less damaging. Too few studies of neuropsychological function have been published after alternative forms of central nervous system prophylaxis. The best way to prevent leukaemia of the central nervous system has to be determined and may vary with the age of the patient and the clinical features at presentation. Meanwhile, cranial irradiation and intrathecal methotrexate remain the best established way to prevent this chronic and distressing complication of childhood leukaemia.

JUDITH M CHESSELLS

Consultant Physician. Department of Haematology and Oncology, Hospital for Sick Children. London WC1N 3JH

- 1 Medical Research Council. Treatment of acute lymphoblastic leukaemia: effect of "prophylactic" therapy against central nervous system leukaemia. Br Med J 1973;ii:381-4.
 Campbell RHA, Marshall WC, Chessells JM. Neurological complications of childhood leukaemia
- rch Dis Child 1977:52:850-8
- 3 Medical Research Council. Effects of varying radiation schedule, cyclophosphamide treatment,
- and duration of treatment in acute lymphoblastic leukaemia. Br Med J 1978;ii:787-91.
 4 Hustu HO, Aur RJA, Verzosa MS, Simone JV, Pinkel D. Prevention of central nervous system leukemia by irradiation. Cancer 1973;32:585-97.
- 5 Moe PH, Seip M, Finne PH. Intermediate dose methotrexate (IDM) in childhood acute lymphocytic leukemia in Norway. Acta Paediatr Scand 1981;70:73-9. 6 Sullivan MP, Chen T, Dyment PG, Huizdala E, Steuber CP. Equivalence of intrathecal
- Suntvari MT, Chen T, Dynien TO, Huzdala E, Steuer CT. Equivalence of initialical chemotherapy and radiotherapy as central nervous system prophylaxis in children with acute lymphatic leukemia: a pediatric oncology group study. Blood 1982;66:948-58.
 Soni SS, Marten GW, Pitner SE, Duenas DA, Powazek M. Effects of central nervous system irradiation on neuropsychologic functioning of children with acute lymphocytic leukemia. N
- Engl 7 Med 1975;293:113-8.
- 8 Maguire P, Comaroff J, Ramsell PJ, Jones PHM. Psychological and social problems in families of children with leukaemia. In: Jones PHM, ed. Topics in paediatrics I. Haematology and oncology. Tunbridge Wells: Pitman Medical, 1979:141-9.
- 9 Eiser C, Lansdown R. Retrospective study of intellectual development in children treated for acute lymphoblastic leukaemia. Arch Dis Child 1977;52:525-9.
- 10 Eiser C. Effects of chronic illness on intellectual development. A comparison of normal children with those treated for childhood leukaemia and solid tumours. Arch Dis Child 1980;55:766-70.
- 11 Moss HA, Nannis ED, Poplack DG. The effects of prophylactic treatment of the central nervous system on the intellectual functioning of children with acute lymphocytic leukemia. Am J Med 1981:71:47-52
- 12 Jannoun L. Are cognitive and educational development affected by age at which prophylactic therapy is given in acute lymphoblastic leukaemia? Arch Dis Child 1983;58:953-8. 13 Meadows A, Gordon J, Massari DJ, Littman P, Fergusson J, Moss K. Declines in IQ scores and
- cognitive dysfunctions in children with acute lymphocytic leukaemia treated with cranial irradiation. Lancet 1981;ii:1015-8.
- 14 Rowland JH, Glidewell OJ, Sibley RF, et al. Effects of different forms of central nervous system prophylaxis on neuropsychologic function in childhood leukaemia. Journal of Clinical Oncology 1984:2:1327-35
- 15 Esseltine DW, Freeman CR, Chevalier R, et al. Computed tomography brain scans in long term survivors of childhood acute lymphoblastic leukemia. Med Pediatr Oncol 1981;9:429-38. 16 Ochs JJ, Parvey LS, Whitaker JN, et al. Serial cranial computed tomography scans in children
- with leukemia given two different forms of central nervous system therapy. Journal of Clinical Oncology 1983;1:793-8.
- 17 Shalet SM, Beardwell CG, Pearson D, Morris-Jones PH. The effect of varying doses of cerebral irradiation on growth hormone production in childhood. Clin Endocrinol 1976;5:287-
- 18 Ahmed SR, Shalet SM. Hypothalamic growth hormone releasing factor deficiency following cranial irradiation. Clin Endocrinol 1984;21:483-8.
- Shalet SM, Beardwell CG, Twomey JA, Jones PHM, Pearson D. Endocrine function following the treatment of acute leukemia in childhood. *J Pediatr* 1977;90:920-3.
 Shalet SM, Price DA, Beardwell CG, Jones PHM, Pearson D. Normal growth despite abnormalities of growth hormone secretion in children treated for acute leukemia. *J Pediatr* 1979:94:719-22.
- 21 Deeg J, Storb R, Thomas ED. Bone marrow transplantation: a review of delayed complications Br 7 Haematol 1984:57:185-208.
- 22 Nesbit ME, Sather HN, Robison LL, et al. Presymptomatic central nervous system therapy in previously untreated childhood acute lymphoblastic leukaemia. Comparison of 1800 rad and 2400 rad. Lancet 1981;i:461-5.

Phantom pregnancy

Pseudocyesis is a condition in which a non-pregnant-and non-psychotic-woman firmly believes herself to be pregnant and develops objective signs of pregnancy.¹ Most cases are said to occur between the ages of 20 and 39, though the age range in one series was 5-79,² and cases have recently been described in teenagers.³⁻⁵ The most common symptom is amenorrhoea or oligomenorrhoea, usually for nine months.6 There is also abdominal enlargement, but without effacement of the umbilicus. Breast changes, which occur in 80% of patients,² include tenderness and swelling, secretion of milk or colostrum, and areolar pigmentation. Patients often claim to feel fetal movements, usually earlier than in a genuine pregnancy.1 There may be vomiting, morning nausea, aberrations of appetite, and weight gain, and a case of "toxaemia" has been reported.6 The diagnosis may be difficult,⁷ but nowadays should easily be made with the help of ultrasound.8 Occasional cases have been described in men,²⁹ but these may be associated with psychosis or organic disease.9

Phantom pregnancy was first described by Hippocrates and has since affected all races and strata of society, including British royalty, American slaves, and Chinese coolies.² It seems to be becoming rarer,12 partly because increasing diagnostic accuracy means that it is no longer confused with conditions like hyperprolactinaemia, partly because in developed countries there is less pressure on women to become pregnant, and partly because of increasing public knowledge about medical matters. Nevertheless, the incidence is still comparatively high among black people in Africa,¹⁰¹¹ and in developed countries immigrants may remain at risk.^{3-5 12} Patients are usually naive about medical matters,¹³ and may have either a strong desire for pregnancy or a fear of conceiving.¹⁴ The condition may be a form of hysterical conversion,3 or depression may be present.1614 A "pregnancy" may help a woman cope with distress or loss,^{6 15} and an association with child stealing has been reported.¹²

What is the endocrine mechanism of pseudocyesis? In laboratory rats pseudopregnancy may be induced by various means, including genital stimulation,^{2 16} and is due to persistence of a corpus luteum in the absence of pregnancy; neurogenic suppression of prolactin inhibitory factor may occur, allowing prolactin to help maintain the corpus luteum.¹⁷ In human pseudocyesis, however, a corpus luteum is often absent^{2 17} and the basal plasma prolactin concentration may be normal^{18 19} or raised.^{5 17} Basal plasma concentrations of follicle stimulating hormone are normal,^{5 17-19} while the luteinising hormone value may be normal¹⁷⁻¹⁹ or raised.⁵ The pulsatile pattern of luteinising hormone and prolactin secretion is exaggerated,⁵ and administration of luteinising hormone releasing hormone and thyrotrophin releasing hormone produces exaggerated responses of luteinising hormone and prolactin respectively.¹⁷⁻¹⁹ In a recent study of five patients in Florida the gonadotrophin concentrations were within the normal range but luteinising hormone was consistently higher than follicle stimulating hormone, while prolactin and progesterone were mildly increased.¹³ Apart from the raised progesterone value this pattern is similar to that in polycystic ovary disease.

In some types of amenorrhoea—particularly hyperprolactinaemic amenorrhoea-there are increased concentrations of opioid peptides (endorphins). These inhibit pulsatile release of luteinising hormone,20 and thus administration of the opioid antagonist naloxone to these women stimulates release of luteinising hormone. Since opioid peptides may influence behaviour as well as hormone concentrations it was suggested that their production might be increased in pseudocyesis; but when naloxone was given to women with pseudocyesis it failed to induce release of luteinising hormone or prolactin.¹³ After the patients were told their diagnosis, however, the naloxone response appeared to return to normal. This suggests that pseudocyesis is not associated with increased opioid activity, though possibly there may be a reduction in tonic opioid inhibition.

Treatment usually entails confronting the patient with the diagnosis.¹⁵ Normally when this is done hormone concentrations return to normal quickly, the abdominal distension begins to disappear,⁵ and there may even be a rapid drop in weight.²¹ Nevertheless, patients may resist the diagnosis,¹² and once they realise the truth depressive illness may occur.7 Recurrence is common,^{2 4 14} and close cooperation between gynaecologist and psychiatrist is important.7 Psychotherapy^{2 14 15} and family therapy⁴ may be necessary, and appropriate follow up is essential.14 21

JAMES OWEN DRIFE

Senior Lecturer in Obstetrics and Gynaecology, University of Leicester, Leicester LE2 7LX

1 Murray JL, Abraham GE. Pseudocyesis: a review. Obstet Gynecol 1978;51:627-31

- Cohen LM. A current perspective of pseudocyesis. Am J Psychiatry 1982;139:1140-4.
 Hardwick PJ, Fitzpatrick C. Fear, folie and phantom pregnancy: pseudocyesis in a fifteen-year-
- old girl. Br 7 Psychiatry 1981;139:558-62.